Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi

Michele Merli,Carlo Visco,Michele Spina,Stefano Luminari,Virginia Valeria Ferretti,Manuel Gotti,Sara Rattotti,Valeria Fiaccadori,Chiara Rusconi,Clara Targhetta,Caterina Stelitano,Alessandro Levis,Achille Ambrosetti,Davide Rossi,Luigi Rigacci,Alfonso Maria D’Arco,Pellegrino Musto,Annalisa Chiappella,Luca Baldini,Maurizio Bonfichi,Luca Arcaini,M. Merli,C. Visco,M. Spina,S. Luminari,V. V. Ferretti,M. Gotti,S. Rattotti,V. Fiaccadori,C. Rusconi,C. Targhetta,C. Stelitano,A. Levis,A. Ambrosetti,D. Rossi,L. Rigacci,A. M. D'Arco,P. Musto,A. Chiappella,L. Baldini,M. Bonfichi,L. Arcaini
DOI: https://doi.org/10.3324/haematol.2013.094318
2013-11-22
Haematologica
Abstract:A specific prognostication score for hepatitis C virus-positive diffuse large B-cell lymphomas is not available. For this purpose, the Fondazione Italiana Linfomi (FIL, Italian Lymphoma Foundation) carried out a multicenter retrospective study on a large consecutive series of patients with hepatitis C virus-associated diffuse large B-cell lymphoma to evaluate the prognostic impact of clinical and virological features and to develop a specific prognostic score for this subset of patients. All prognostic evaluations were performed on 535 patients treated with an anthracycline-based induction regimen (with rituximab in 255 cases). Severe hepatotoxicity was observed in 14% of patients. The use of rituximab was not associated with increased rate of severe hepatotoxicity. Three-year overall survival and progression-free survival were 71% and 55%, respectively. At multivariate analysis, ECOG performance status of 2 or over, serum albumin below 3.5 g/dL and HCV-RNA viral load over 1000 KIU/mL retained prognostic significance. We combined these 3 factors in a new "HCV Prognostic Score" able to discriminate 3 risk categories with different overall and progression-free survival (low=0; intermediate=1; high-risk ≥2 factors; P<0.001). This score retained prognostic value in the subgroups of patients treated with and without rituximab (P<0.001). The new score performed better than the International Prognostic Index at multivariate analysis and Harrel C-statistic. With the use of three readily available factors (performance status, albumin level and HCV-RNA viral load), the new "HCV Prognostic Score" is able to identify 3 risk categories with different survival, and may be a useful tool to predict the outcome of hepatitis C virus-associated diffuse large B-cell lymphomas.
hematology
What problem does this paper attempt to address?